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Abstract 33 
Background: Hypothyroidism has been associated with increased pulmonary morbidity and overall 34 
mortality. We conducted a systematic review to identify the prevalence and underlying mechanisms 35 
of respiratory problems among patients with thyroid insufficiency. 36 
 37 
Methods: PubMed and EMBASE databases were searched for relevant literature from January 1950 38 
through January 2015 with study eligibility criteria: English-language publications; Adult 39 
subclinical or overt hypothyroid patients; Intervention, observational or retrospective studies; 40 
and respiratory manifestations. We followed the PRISMA statement and used the Cochrane’s risk 41 
of bias tool. 42 
 43 
Results: A total of 1699 papers were screened by two independent authors for relevant titles. Of 109 44 
relevant abstracts, 28 papers underwent full text analyses, of which 22 were included in the review. 45 
We identified possible mechanisms explaining respiratory problems at multiple physiological 46 
levels such as the ventilator control system, diaphragmatic muscle function, pulmonary gas 47 
exchange, goiter caused upper airway obstruction, decreased capacity for energy transduction, and 48 
reduced glycolytic activity. 49 
Obstructive sleep apnea syndrome was found among 30% of newly diagnosed patients with overt 50 
hypothyroidism, and demonstrated reversibility following treatment. The evidence for or against a 51 
direct effect on pulmonary function was ambiguous. However, each of the above mentioned areas 52 
were only dealt with in a limited number of studies. 53 
Therefore, we refrain from giving strong conclusions on any of these themes. Moreover, most 54 
studies were hampered by considerable risk of bias due to e.g. small numbers of patients, lack of 55 
control groups, randomization and blinding, and differences in BMI, gender, and age 56 
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between subjects and controls. 57 
 58 
Conclusion: Mechanistic data, linking hypothyroidism and respiratory function are at best limited. 59 
This area of research is therefore open for retesting hypotheses, using appropriate study designs and 60 
methods. 61 
Systematic review registration number on PROSPERO: CRD42015016815. 62 
 63 
  64 
   
4 
 
Introduction 65 
Overt hypothyroidism is a common endocrine condition, which affects 1-2% of adults 66 
(1), while subclinical hypothyroidism has been reported in 4-20% (2). It is most often caused by 67 
autoimmunity, but may also be a consequence of radioiodine treatment or thyroid surgery as the 68 
most prominent other causes (3-5). Hypothyroidism may give rise to many physical (6) and mental 69 
symptoms (6, 7) and is associated with increased mortality (8). The increased mortality might, at 70 
least partly, be explained by increased pre-existing pulmonary morbidity, or excess pulmonary co-71 
morbidity after the diagnosis of hypothyroidism (8, 9). In the extremely rare but potentially deadly 72 
case of myxedema coma, the severe thyroid failure has a direct effect on the respiratory function via 73 
the ventilator control system (carotid glomus and brain stem respiratory centers) (10, 11). Upper 74 
airway obstruction (UAO) may also contribute to the pulmonary morbidity, either by the presence 75 
of a goiter in classical Hashimoto’s thyroiditis or from macroglossia, thickening of vocal cords, and 76 
mucopolysaccharide deposits in the respiratory tract, as observed in patients with severe myxedema 77 
(11-13). However, several other factors probably contribute to the link between hypothyroidism, the 78 
respiratory system, and increased mortality.  79 
Here, based on the observed increased mortality and pulmonary co-morbidity, we aim 80 
at investigating – by a literature review - the impact of hypothyroidism on pulmonary function and 81 
the respiratory system, an issue very sparsely addressed previously.  82 
 83 
Methods 84 
We performed a systematic review according to the Preferred Reporting Items for 85 
Systematic reviews and Meta-Analyses (PRISMA) statement (14). Methods as well as inclusion and 86 
exclusion criteria were specified in advance in a review protocol, which can be accessed at 87 
http://www.crd.york.ac.uk/PROSPERO/ by registration no. CRD42015016815.  88 
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English-language publications on the relationship between respiratory function and 89 
hypothyroidism, accessible in PubMed and EMBASE databases (January 1 1950 – January 31 90 
2015), were identified. We used the PICOS approach (Population, Intervention, Comparison, 91 
Outcome and Study design) for setting the research question (15). All studies dealing with overt or 92 
subclinical hypothyroid patients were considered if the outcome was related to the respiratory 93 
function. Both observational and interventional studies were accepted, irrespective of whether the 94 
design was retrospective, cross sectional, or prospective. No comparator group was necessary. We 95 
performed the last search on February 20, 2015. The full search strategy is provided in the 96 
appendix. 97 
 98 
Literature search 99 
Two authors (JS and KW) independently screened the titles and abstracts. They 100 
decided, by consensus, which articles to evaluate in full text. We searched for outcomes related to 101 
neurological ventilatory control, pulmonary gas exchange, pulmonary function, respiratory strength, 102 
and sleep apnea. Only English language articles were included. The exclusion criteria were: case 103 
reports, expert opinions, letters, reviews, and studies conducted in pregnant patients or those with 104 
thyroid cancer. Multiple reports of the same set of data were assessed, and only the most 105 
representative or updated report was included. We screened the reference lists of included full text 106 
articles for missing publications. The same two authors extracted data independently, according to a 107 
pre-specified data collection sheet. Disagreements were resolved by discussion. The following data 108 
were extracted: type and design of the study, first authorship, country of origin, year of publication, 109 
number of patients, demographics, severity of hypothyroidism, type of intervention if relevant, time 110 
of post-intervention follow-up, and outcome parameters. The ‘Cochrane risk of bias tool’ was used 111 
to assess the risk of bias in each of the included articles (16).  112 
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 113 
Results 114 
We identified 1690 relevant titles from PubMed and EMBASE and nine from the 115 
reference lists of included papers (Figure 1). We excluded 1672 titles, after review of titles and 116 
abstracts, leaving twenty-eight for full text evaluation. Six full text papers failed to meet the 117 
inclusion criteria resulting in twenty-two papers for the final analyses. No randomized double blind 118 
placebo controlled studies were identified.  119 
Applying the ‘Cochrane Risk of Bias tool’ across studies, we found a considerable 120 
risk of bias as many studies failed to describe inclusion procedures, include control groups, 121 
randomize for treatment, blind observers or participants, or failed to report data previously 122 
described in the method section (Table 1). As a consequence, we made no attempt to perform a 123 
meta-analysis.  124 
Most of the included studies (Table 2) were small, with fifty or fewer individuals in 125 
thirteen of the twenty-two studies. Sixteen studies included overt hypothyroid patients only, and 126 
four studies included subclinical hypothyroid patients only. The two remaining studies included 127 
both groups of hypothyroid patients. There were thirteen intervention studies, eight prospective 128 
observational studies, and one retrospective observational study.  129 
 130 
INSERT FIGURE 1, TABLE 1 AND TABLE 2 AROUND HERE 131 
 132 
Respiratory symptoms and ventilation 133 
We identified six studies addressing the effect of overt or subclinical hypothyroidism 134 
on respiratory symptoms and ventilation. Four of the six studies had substantial risk of bias in their 135 
study design (Table 1), defined as using neither randomization, nor allocation concealment or 136 
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blinding. Among 124 (17) and 20 (18) patients with overt hypothyroidism, two observational 137 
studies with severe risk of bias (Table 1) found increased respiratory symptoms, including shortness 138 
of breath, sputum production, cough, wheezing, and airway hyper-responsiveness, with an odds 139 
ratio of 2.7-3.5, when compared to 1346 healthy controls.  140 
It has been debated whether pleural effusion, due to overt hypothyroidism, causes 141 
some of the respiratory symptoms in patients with thyroid failure. A single study with high risk of 142 
bias (Table 1) found that the effusions in such patients were primarily due to other diseases than 143 
hypothyroidism (19).  144 
A study of overt hypothyroid patients found that the response to hypercapnia and 145 
hypoxia was reduced initially, improved seven days after either triiodothyronine (LT3) or 146 
levothyroxine (LT4) treatment, and normalized in most patients after 12-24 weeks of LT4 treatment 147 
only (20). That study, however, was hampered by 25% of the patients being lost to follow-up. 148 
Another study failed to reproduce these results (21), may be due to a sample size half of that used in 149 
the previous study. In a non-blinded study, including patients with overt or subclinical 150 
hypothyroidism, the end-tidal CO2 was reduced (22). This finding is surprising, but most likely 151 
explained by hyperventilation at the time of examination.  152 
Based on these data, no clear conclusions can be made regarding the impact of 153 
hypothyroidism on respiratory symptoms and ventilation. The included studies all use different 154 
assessment techniques, and are hampered by substantial risk of bias. We therefore refrain from 155 
giving any conclusions on this topic. Only two studies have addressed the effects of LT4 156 
substitution on ventilation (20, 21). Both studies suffer from a high risk of observer bias, and they 157 
present opposing results, which renders a conclusion impossible (Table 3). 158 
 159 
Pulmonary function  160 
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The results from the eleven studies addressing the influence of overt or subclinical 161 
hypothyroidism on pulmonary function are contradictory. Nine of the eleven studies have study 162 
designs with considerable risk of bias (Table 1). Three studies addressed the impact of overt 163 
hypothyroidism on the diaphragmatic and abdominal muscle strength, and offer contradictory 164 
results (21, 23, 24). Two studies, one with 43 patients (23) and another with 24 patients (24), found 165 
that the diaphragmatic muscle strength improved by either LT4 or LT3 treatment. A third study, 166 
including 20 patients, found no improvement after LT4 treatment (21). All three studies included a 167 
limited number of participants and can therefore not be the foundation of strong conclusions (21, 168 
23, 24).  169 
In subclinical hypothyroidism, a single study found a reduced diaphragmatic 170 
inspiratory and expiratory strength, but the results were invalidated by 3.7 times more men being 171 
included in the control group than in the study group (25). As for the diaphragmatic inspiratory 172 
strength, no change in this parameter has been demonstrated in this group of patients (26).  173 
Two studies comprising 267 (25) and 120 patients (27) suffering from subclinical 174 
hypothyroidism, found the Forced Vital Capacity (FVC) reduced by more than 250 ml, and the 175 
Forced Expiratory Volume in 1 second (FEV1) reduced by 190 ml, as compared with healthy 176 
participants. A study of 20 overt hypothyroid patients showed similar findings compared to healthy 177 
participants (28). Although the results may seem unequivocal, they should be interpreted with 178 
caution, as the study and control groups were not comparable with respect to sex, age, and BMI. 179 
Apart from these three reports, the majority of studies showed no impact of thyroid 180 
dysfunction on pulmonary function when using pulmonary function tests (18, 24, 29-31), most 181 
likely because of small sample sizes (21-45 patients). The lack of a control group - with a few 182 
exceptions (18, 24, 30) - is clearly another limitation of these studies. One study, with 43 overt 183 
hypothyroid patients (23), found that the pulmonary function improved after initiation of LT4, 184 
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despite the fact that it was not affected at baseline. Other studies with fewer patients could not 185 
reproduce this finding (24, 29-31), which might be due to limited power.  186 
As the majority of the studies have serious methodological limitations, it is difficult, if 187 
not impossible, to make any clear conclusions regarding the impact of hypothyroidism, or the effect 188 
of LT4 therapy, on the diaphragmatic muscle strength and pulmonary function (Table 3).  189 
 190 
Obstructive sleep apnea syndrome 191 
We identified seven studies which investigated the impact of overt or subclinical 192 
hypothyroidism on obstructive sleep apnea syndrome (OSAS). Three of the seven studies carried a 193 
significant risk of bias. Comparison across studies is difficult as study designs, populations, and the 194 
employed techniques varied.  195 
Nocturnal breathing abnormalities, such as restless sleep, snoring, choking, and in 196 
severe cases apnea periods, occurred among 25-50% of patients with overt hypothyroidism (32-35). 197 
One study found that 30% of patients with recently diagnosed primary overt hypothyroidism 198 
suffered from OSAS, according to well defined criteria (34). In these patients, OSAS was reversed 199 
by LT4 treatment (34). The other studies were limited by differences in BMI between control and 200 
patient groups, presence of goiter, small patient numbers, or missing data on thyroid hormone 201 
levels. After LT4 replacement therapy, all interventional studies demonstrated a significant 202 
reduction in apnea periods, oxygen desaturation events, and in snoring and choking (33-37). In 203 
subclinical hypothyroidism, one study from a specialized sleep clinic (38) found that 53% of the 204 
patients had OSAS. However, a similar high rate of OSAS was found among euthyroid subjects, 205 
probably reflecting selection bias in that study.  206 
We conclude that overt hypothyroidism seems to be linked to sleep apnea syndrome, 207 
with improvement after LT4 substitution, as shown in four of six studies (Table 3). The evidence of 208 
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subclinical hypothyroidism being linked with sleep apnea syndrome is vaguer as only one study 209 
with serious methodological limitations addressed this issue. 210 
 211 
INSERT TABLE 3 AROUND HERE 212 
 213 
Discussion 214 
We undertook a systematic review with the aim of elucidating the type and magnitude 215 
of respiratory problems among patients with hypothyroidism and, if possible, to identify the 216 
underlying physiological mechanisms. Unfortunately, many of the studies, on which we base this 217 
review, are hampered by considerable heterogeneity, generally low participant numbers, and high 218 
risk of observer and selection bias. We gave most credence to the studies with the least bias and 219 
weighted these highest in our conclusions, which, however, still are rather vague.  220 
 221 
Overt and subclinical hypothyroidism 222 
Overt hypothyroidism may be associated with an increased risk of respiratory 223 
symptoms (19). Such patients may also have a decreased control of breathing in response to 224 
hypercapnia and hypoxia (20), diminished diaphragmatic muscle strength (23, 24), and higher 225 
propensity to develop sleep apnea (34). These statements are, however, associated with great 226 
uncertainty as the evidence is sparse. Additionally, the few studies, conducted within this area, are 227 
hampered by considerable observer and selection bias as they rarely use blinding or randomization 228 
in their designs.  229 
In case of subclinical hypothyroidism, patients may have reduced diaphragmatic 230 
muscle strength and lower FVC and FEV1, according to two studies (25, 27), but these results 231 
should be interpreted with caution since the male/female ratio was higher in the control groups. 232 
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Whether patients with subclinical hypothyroidism suffer from unrecognized sleep apnea syndrome 233 
is unclarified (38). 234 
 235 
Thyroid hormone substitution 236 
In overt hypothyroid patients, both LT3 and LT4, taken separately, improved the 237 
response to hypercapnia and hypoxia as soon as seven days after initiation of treatment (20), with 238 
normalization after 2-5 months of LT4 therapy only (20). The diminished diaphragmatic muscle 239 
strength normalized within three months of LT4 or LT3 treatment, in both subclinical and overt 240 
hypothyroid patients (23-25). As the evidence of an effect of hypothyroidism on the pulmonary 241 
function is too weak to make a conclusion, the evidence of a direct effect of LT3 or LT4 242 
substitution likewise becomes inadequate to allow any conclusion on this topic (24, 29-31).  243 
In hypothyroid patients with sleep apnea, most studies demonstrate an effect of LT4 244 
therapy in reducing or even eliminating nocturnal apnea periods (33-37).  245 
No studies have investigated the treatment effects of LT3 compared to LT4 on 246 
respiratory symptoms, ventilation, pulmonary function, diaphragmatic function, or sleep apnea. 247 
 248 
Upper airway obstruction and hypothyroidism 249 
When hypothyroidism is caused by Hashimoto’s thyroiditis, the effect of LT4 250 
treatment can in part be explained by the reduction in thyroid size following restoration of 251 
euthyroidism (39, 40). UAO does not always lead to subjective symptoms and may therefore be 252 
overlooked in patients with thyroid disease (41). However, while thoroughly studied in nontoxic 253 
goiter (12), there are no studies on the pulmonary effect following goiter reduction in Hashimoto’s 254 
thyroiditis.  255 
The majority of Hashimoto’s thyroiditis patients do not have a goiter. However, when 256 
present, a goiter can cause UAO by tracheal compression, as seen in 14-31% of patients referred for 257 
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evaluation of simple goiter (41, 42), and in 26-60% of patients referred to thyroidectomy (43-45). 258 
UAO, due to dislocation of the trachea or decrease of tracheal cross-sectional area, can have a 259 
pronounced effect on the airflow (41, 42, 46), which is significantly improved by goiter volume 260 
reduction (47, 48). Tracheal compression is somewhat more frequent when the goiter has a 261 
substernal location (35-73%), compared to a cervical location (9-58%) (49-53). Tracheal 262 
compression might not lead to symptoms, but is nevertheless a relevant consideration, as UAO may 263 
develop into life-threatening respiratory insufficiency (41, 54-56). The extent to which these factors 264 
are at play in hypothyroid individuals is unknown. 265 
 266 
Hypothyroidism and respiration in experimental animal models 267 
Based on studies in experimental animal models, the brain stem, peripheral 268 
chemosensors, ATP generating enzymes, and muscle function, seem to be affected by 269 
hypothyroidism. Studies in hamsters - as in man (20) - have identified a decreased response 270 
(breathing frequency) to hypoxia and hypercapnia three months after development of 271 
hypothyroidism (57-59). This is caused by diminished dopamine receptor (D1) protein levels in the 272 
respiratory centers of the brain stem (paraventricular nucleus of the hypothalamus [PVN] and 273 
solitary nucleus), and the carotid glomus (57). Dopamine receptor (D2) levels are increased in the 274 
striatum and carotid glomus in the hypothyroid state, contrasting with the reduction of these 275 
receptor levels in the PVN (58).  276 
A reduced diaphragmatic muscle strength - as seen in some human studies (23-25) - 277 
may be explained by studies in thyroidectomized rats (60). Here, a decreased capacity for energy 278 
transduction and glycolysis due to diminished enzyme levels (succinate dehydrogenase, hexokinase, 279 
3-hyroxyl-CoA dehydrogenase, and phosphofructokinase) in the thoracic diaphragm has been found 280 
(60). Another study analyzing diaphragmatic muscle fibers from propylthiouracil-induced 281 
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hypothyroidism in rats showed a decreased maximum force and myosin heavy chain2B/2X content 282 
(61). 283 
From the aforementioned, there are many pathways to the diminished respiratory 284 
function, but it is clear that much remains to be explored in order to clarify how transient or 285 
permanent hypothyroidism, as well as LT4 treatment, affect the respiratory system.  286 
 287 
Limitations  288 
In our search for evidence of the impact of hypothyroidism on respiratory function, we 289 
encountered a paucity of high-quality data. No randomized controlled studies were conducted either 290 
in subclinical disease or in overt hypothyroidism in combination with medical treatment. Also many 291 
studies have a skewed balance between males and females, probably just reflecting the female 292 
preponderance of this disorder. Nevertheless, this, as well as the small study populations, questions 293 
whether the findings can be generalized to a broader population of hypothyroid individuals. 294 
Furthermore, many of the older studies do not address the potential confounding effect of the co-295 
existence of goiter, if present. 296 
We have not included patients with pre-existing pulmonary disease. Therefore, we 297 
cannot dissect whether hypothyroidism merely adds to the severity of pre-existing pulmonary 298 
disease or is the cause of de novo respiratory disease. There is some evidence that especially 299 
autoimmune hypothyroidism may be related to pulmonary diseases such as asthma and chronic 300 
obstructive pulmonary disease, but this area is sparsely investigated (62, 63). 301 
As hypothyroidism affects multiple organ systems, the distinction between a primary 302 
pulmonary effect and an effect mediated via the nervous system, the cardiopulmonary system or the 303 
skeletal muscles is far from clear-cut. We did not include any data on cardiovascular or muscle 304 
function in our analyses, which might limit the generalizability of our findings. The impact of 305 
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hypothyroidism on exercise capacity has been covered in a recent systematic review by Lankhaar et 306 
al. (64), who identified multiple causes of exercise intolerance due to disturbances in the 307 
cardiovascular-, cardiopulmonary-, musculoskeletal-, neuromuscular-, and cellular metabolic 308 
systems (64). Persisting complaints of exercise intolerance was found in a subgroup of subclinical 309 
hypothyroid patients not responding with symptom relief, despite adequate treatment with LT4 (64).  310 
 311 
Implications for the future   312 
Regarding the impact of overt hypothyroidism on respiratory symptoms, ventilation, 313 
and diaphragmatic muscle strength, no conclusions can be provided due to the small number of 314 
studies and the significant methodological weaknesses. Thus, this area of research is open for 315 
retesting hypotheses regarding the effects of hypothyroidism on various features of the respiratory 316 
system, employing prospective study designs, validated methods, and blinded assessments. The 317 
influence of overt hypothyroidism on the diaphragmatic function should also be further explored, 318 
since this unique thoraco-abdominal muscle has an important role in forming the voice, cough, and 319 
for exercise capacity. As for subclinical hypothyroidism, it remains uncertain whether the ventilator 320 
response to hypoxia and hypercapnia is affected, or whether these patients are more prone to suffer 321 
from sleep apnea syndrome than the background population.  322 
Importantly, as most patients diagnosed with hypothyroidism are substituted with 323 
LT4, data on the long-term impact of persistent hypothyroidism on the respiratory function is 324 
virtually non-existent. 325 
 326 
Conclusions 327 
 The evidence of an impact of hypothyroidism on respiratory function is at best limited. We 328 
found no information linking the effect of hypothyroidism on respiratory function to the increased 329 
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mortality from pulmonary diseases, as reported previously from registry-based data (8). In contrast 330 
to the considerable knowledge regarding the influence of hypothyroidism on the cardiovascular 331 
system (65, 66), many aspects of the influence on the respiratory function have been inadequately 332 
addressed or not explored at all.  333 
 334 
 335 
  336 
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Table 1:  
Risk of bias summary in the 22 studies included for review. Unclear risk of bias (?), low risk of bias (+), and high risk of bias (-). 
 
 
Study 
Random sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of 
outcome 
assessment 
Incomplete 
data 
Selective 
reporting 
Other bias 
Birring 2003 (17) + ? ? ? + ? + 
Birring 2005 (18) + ? + + + ? + 
Gottehrer 1990 (19) ? ? ? ? + ? + 
Ladenson 1988 (20) ? ? ? ? + ? + 
Duranti 1993 (21) ? ? ? ? + - ? 
Ansarin 2011 (22) ? ? ? ? + ? + 
Siafakas 1992 (23) ? ? ? ? + ? + 
Gorini 1989 (24) ? ? ? ? - ? ? 
Cakmak 2011 (25) - ? ? ? + ? - 
Reuters 2009 (26) ? ? + + + ? + 
Cakmak 2007 (27) ? ? ? ? - ? + 
Swami 2010 (28) ? ? ? ? + ? - 
Wilson 1960 (29) - ? ? ? + ? ? 
Ambrosino 1985 (30) ? ? ? ? - ? + 
Koral 2006 (31) ? ? ? ? + ? - 
Pelttari 1994 (32) ? ? + + + ? - 
Lin 1992 (33) ? ? + + + ? ? 
Jha 2006 (34) ? ? + + + ? + 
Hira1999 (35) ? ? + + - ? + 
Misiolek 2007 (36) ? ? ? ? - ? - 
Rajagopal 1984 (37) ? ? ? ? - ? - 
Resta 2005 (38) ? ? ? ? + ? - 
  
Table 2:  
Included studies regarding the respiratory manifestations of hypothyroidism. Observational (OB), Interventional (IN), Retrospective (RE), 
Overt hypothyroidism (HT), Subclinical hypothyroidism (sHT), Thyrotropin (TSH), Levothyroxine (LT4), Triiodothyronine (LT3) 
Questionnaire (Quest), Carbon dioxide measurements (CO2), Carbon monoxide (CO), Manovacumeter (MVM), Pulmonary function test 
(PFT), Forced Vital Capacity (FVC), Forced Expiratory volume 1 second (FEV1), Polysomnography (PSG), Obstructive sleep apnea 
(OSAS), Apnea Hypopnea Index (AHI) and Respiratory Disturbance Index (RDI). Age: mean (years). TSH is given as the mean value 
(mIU/l) at time of diagnosis. Non-available: NA 
 
Study Design n Age Cohort Methods Results  
Birring 2003 (17) OB 1534 56 HT (primary), TSH: NA Quest Breathlessness, sputum and cough more prevalent.  
Birring 2005 (18) IN 45 52 HT (primary), TSH 2  PFT No change in PFT. Increase in respiratory symptoms. 
Gottehrer 1990 (19) RE 128 NA HT (primary), TSH: NA X-ray Pleural effusions rarely caused by hypothyroidism. 
Ladenson 1988 (20) IN 38 50 HT (primary), TSH: 97  MVM 
Depressed response to hypoxia and hypercapnia. Improved within one week 
of LT3 or LT4 treatment in 75 % of patients. Normalized after LT4 for 12-
24 weeks. 
Duranti 1993 (21) IN 20 54 HT (primary), TSH > 64  MVM, PFT No change in ventilator control systems or diaphragmatic strength after LT4. 
Ansarin 2011 (22) OB 95 35 sHT/HT (NA), TSH: 8/44  CO2 Reduced alveolar ventilation or hypoventilation in both groups. 
Siafakas 1992 (23) IN 43 54 
HT (various causes), TSH: 
55  
MVM PFT 
Diaphragmatic in- and expiratory strength, FVC and FEV1 improved after 
LT4.  
Gorini 1989  (24) IN 24   42 HT (surgery), TSH: 44  PFT No change in PFT. FVC and PiMax improved after LT3. 
Cakmak 2011 (25) OB 184 46 sHT (NA), TSH: 11  PFT Reduced diaphragmatic strength, FVC and FEV1. 
Reuters 2009 (26) OB 68 47 
sHT (various causes), 
TSH: 5  
MVM No difference in inspiratory strength. 
Cakmak 2007 (27) OB 267 43 
sHT/HT (NA), TSH: 
10/74  
PFT Reduced FVC and FEV1.  
Swami 2010 (28) IN 40 40 HT (NA), TSH: 14  PFT Reduced FVC and FEV1.  
Wilson 1960 (29) IN 26 51 HT (NA), TSH: NA PFT No effect of LT3/desiccated thyroid on PFT. 
Ambrosino 1985 (30) IN 21 37 HT (surgery), TSH: 51  PFT No change in PFT and no effect of LT3.  
Koral 2006 (31) IN 38 43 sHT (NA), TSH: 13  PFT No effect of LT4 on PFT. 
Pelttari 1994 (32) OB 214 43 HT (NA), TSH > 10  PSG 50 % had nocturnal breathing abnormalities. 
Lin 1992 (33) IN 85 46 HT (NA), TSH > 25  PSG 25 % had mild to severe OSAS. Improved after LT4. 
Jha 2006 (34) IN 50 34 HT (primary), TSH: 100  PSG 30 % had AHI > 5. Reversible after LT4. 
Hira1999 (35) IN 20 33 HT (NA), TSH: NA PSG 45 % had OSAS. Majority resolved after LT4.  
Misiolek 2007 (36) IN 15 50 HT (NA), TSH: 39  RDI No change in RDI, but reduced sleepiness and snoring after LT4.  
Rajagopal 1984 (37) IN 9 49 HT (NA), TSH: NA PSG Reduced number of apneas after LT4. 
Resta 2005 (38) OB 108 52 sHT (NA), TSH: 8  PSG 53 % of patients had OSAS, which ameliorated after treatment. 
 
Table 3:  
Recommendations based on strength of evidence. Moderate level of evidence: Further research is likely to have an important impact on our 
confidence in the estimate of effect and may change the estimate. Low level of evidence: Further research is very likely to have an 
important impact on our confidence in the estimate of effect and is likely to change the estimate. 
Levothyroxine (LT4), Forced Vital Capacity (FVC) and Forced Expiratory volume 1 second (FEV1). 
 
Theme Physiological effect Level of evidence Sources 
Ventilation in hypothyroid 
patients 
Affected ventilation 
 
Ventilation normalizes after LT4 treatment 
Low (one or more studies with severe limitations) 
 
Low (one or more studies with severe limitations) 
(20-22) 
Diaphragmatic muscle 
strength in hypothyroid 
patients 
Reduced diaphragmatic muscle strength 
 
Diaphragmatic muscle strength increases after LT4 treatment 
Low (one or more studies with severe limitations) 
 
Low (one or more studies with severe limitations) 
(21, 23-26) 
 
Pulmonary function tests in 
hypothyroid patients 
No change in FVC and FEV1 
 
Increased FVC and FEV1 after LT4 treatment 
Low (one or more studies with severe limitations) 
 
Low (one or more studies with severe limitations) 
(18, 23-24, 25, 27-
31) 
Sleep apnea in hypothyroid 
patients 
Nocturnal breathing abnormalities due to upper airway obstruction 
 
Nocturnal breathing abnormalities reverses after LT4 treatment 
Moderate (several studies with some limitations) 
 
Moderate (several studies with some limitations) 
(32-38) 
 
 
 
